AMYT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	2.38M
Vidutinė apimtis	0.00
Rinkos kapitalizacija	942.77M
EPS	$0 ( 2023-05-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	39.73
ATR14	$0.0580 (0.39%)

Tūris Koreliacija

Ilgas: 0.18 (neutral)

Trumpas: 0.00 (neutral)

Signal:(69.184) Neutral

Amryt Pharma plc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SUMO	0.97
DSPG	0.964
IDCC	0.946
NTUS	0.945
FSTR	0.945
STAY	0.941
HCCI	0.938
SENEA	0.935
SOHOB	0.935
ACLS	0.934

10 Labiausiai neigiamai susiję koreliacijos
DSGN	-0.991
CSSE	-0.989
YTEN	-0.98
FWRD	-0.978
CASA	-0.974
THTX	-0.974
ESPR	-0.97
PFSW	-0.97
GRTX	-0.968
BBLG	-0.963

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Amryt Pharma plc Koreliacija - Valiuta/Žaliavos

0.76
( moderate )

0.88
( strong )

0.83
( strong )

-0.30
( neutral )

-0.33
( neutral )

-0.74
( moderate negative )

Amryt Pharma plc Finansinės ataskaitos

Annual	2021
Pajamos:	$222.54M
Bruto pelnas:	$116.42M (52.32 %)
EPS:	$-0.573

Q3	2022
Pajamos:	$61.13M
Bruto pelnas:	$27.42M (44.86 %)
EPS:	$-0.320

Q2	2022
Pajamos:	$68.54M
Bruto pelnas:	$35.17M (51.32 %)
EPS:	$-0.110

Q1	2022
Pajamos:	$59.13M
Bruto pelnas:	$28.35M (47.95 %)
EPS:	$-0.230

Financial Reports:

No articles found.

Amryt Pharma plc

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.